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ABSTRACT 
 
The vitamin D system plays a role in metabolism regulation. It has been reported that 
1,25(OH)2D3 [1,25-dihydroxyvitamin D] suppresses 3T3-L1 adipocyte differentiation. Vitamin 
D receptor (VDR) knockout mice showed increased energy expenditure whereas mice with 
adipose-specific VDR over expression showed decreased energy expenditure. Brown adipose 
tissue (BAT), which functions in non-shivering thermogenesis by uncoupling ATP synthesis 
from oxidation, plays important roles in energy expenditure. However, the effects of 
1,25(OH)2D3 on brown adipocyte differentiation and mitochondrial respiration have not been 
studied. Reported here is the mRNA expression of VDR, UCP1, and CYP27B1 (1α[alpha]- 
hydroxylase) in two mice models of obesity; and the down regulation of mRNA of VDR, 
CYP24A1 (24-hyrdoxylase), and CYP27B1 during brown adipocyte differentiation in vitro. 
1,25(OH)2D3 dose-dependently suppressed brown adipocyte differentiation, as revealed by oil 
red O (ORO) stained cell morphology, ORO absorbance, and brown adipocyte marker gene 
expression. Moreover, cellular bioenergetics measurements showed that 1,25(OH)2D3 suppressed 
isoproterenol-stimulated oxygen consumption rates (OCR), maximal OCR and OCR from proton 
leak, but had no effects on ATP-generating OCR and spare respiration capacity in brown 
adipocytes. Consistently, over-expression of VDR also suppressed brown adipocyte 
differentiation. Furthermore, both 1,25(OH)2D3 and VDR over expression suppressed PPARγ 
[gamma] transactivation in brown preadipocytes. Taken together, the results demonstrate the 
suppressive effects of 1,25(OH)2D3/VDR signaling on brown adipocyte differentiation and 
mitochondrial respiration and suggest a role of 1,25(OH)2D3/VDR signaling in regulating BAT 
function for obesity treatment and prevention. 
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CHAPTER I  
INTRODUCTION 
 
Obesity, physiologically, is a result of hyperplasia and/or hypertrophy of lipid storing 
adipose tissue [1].  It is defined clinically as having a body mass index ≥30kg/m2 and is currently 
a major health concern in the United States.  In 2010, obesity surpassed smoking as the leading 
contributor to disease; which is not surprising considering the co-morbidities linked to excessive 
fat mass including:  metabolic syndrome, Type 2 diabetes, heart disease, stroke, and cancer [2, 
3].  Paralleling that statistic, the medical costs associated with obesity and its co-morbidities 
accumulated to an astonishing $147 billion dollars in 2008 [2]. With such a strong impact on the 
nation’s health and economy, the exigency to resolve this problem is evident. 
Humans possess two types of fat tissues: white adipose tissue and brown adipose tissue. 
White adipose tissue (WAT) is known for its lipid storing capacity and well-identified 
relationship with nutritional and appetite markers and adipokines such as glucose, leptin, ghrelin, 
and insulin. Moreover, white adipose tissue participates systemic inflammation through the 
secretion of chemokines and cytokines.  
Brown adipose tissue (BAT) functions to produce heat through non-shivering 
thermogenesis. The presence of brown adipose tissue in small eutherian mammals, such as mice, 
provides adequate thermoregulation in a cold environment without compensatory shivering [4]. 
BAT’s thermogenic capacity is conferred by the actions BAT specific uncoupling protein 1 
(UCP1). UCP1, located in the inner mitochondrial membrane of brown adipocytes, uncouples 
ATP synthesis from respiration, resulting in dissipation of heat [5, 6]. Until recently, human 
BAT was thought to exist exclusively in neonates and that maturation, resulting in fat deposition 
and skeletal muscle development, lead to BAT regression. However, positron emission 
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tomography/computed tomography scanning of adult humans has revealed the presence of fat 
depots in the cervical, supraclavicular and paravertebral regions with the characteristics of BAT 
[7-11]. Furthermore, recent gene expression profiling of adult humans has confirmed many 
classical BAT features in the fat depots of the supraclavicular regions [12, 13]. Due to its energy 
expending activity, BAT has become the novel target tissue for combating obesity [14-19]. It has 
been discovered that BAT is negatively associated with BMI, visceral fat, visceral/total fat, waist 
circumference, and diabetes [20, 21]. 
Accumulating evidence suggests that vitamin D has pleiotropic actions that can affect 
multiple organs and metabolic processes, in addition to maintaining calcium homeostasis and 
skeletal health. Recent studies have suggested that WAT is a direct target of vitamin D, and that 
the hormone modulates adipose tissue formation and function [22]. The vitamin D system has 
been implicated in white adipose tissue in terms of inflammation, glucose regulation, 
adipogenesis, and energy metabolism [23-26]. Likewise, the expression of VDR has been 
reported in murine 3T3-L1 preadipocytes [27, 28] and human preadipocytes [29].  
It has also been reported that 1, 25(OH)2D3 inhibits 3T3-L1 adipocyte differentiation [27, 
28], but promotes adipocyte differentiation from human subcutaneous preadipocytes [29]. 
Further, studies of VDR knockout mice and transgenic mice with adipose-specific VDR over-
expression revealed that energy expenditure was markedly higher in VDR knockout mice, but 
reduced in the VDR transgenic mice, compared to their respective controls, suggesting a role of 
the vitamin D system in energy metabolism [30, 31].  
BAT plays a critical role in energy expenditure; however, whether vitamin D system 
modulates brown adipose tissue formation and function has not been studied. The objective of 
the thesis research is to fill in the knowledge gap regarding the effects of vitamin D, specifically 
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vitamin D3, and the vitamin D receptor on brown adipocyte differentiation. By employing a 
brown preadipocyte cell line, the effects of 1,25(OH)2D3 and VDR expression on brown 
adipocyte differentiation were studied. The results presented in this thesis add to our 
understanding of the nutritional regulation of brown adipocyte development and function.  
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CHAPTER II  
LITERATURE REVIEW 
 
2.1 Overview of Vitamin D 
2.1.1 Vitamin D Structure and Function  
Despite being defined as a vitamin, vitamin D is truly a secosteroid hormone. As a 
hormone, vitamin D has a number of calceamic and noncalceamic biological roles. Its classical 
role is associated with bone metabolism as it is required for adequate enterocyte absorption of 
calcium by increasing the expression of calcium channels for uptake in the intestine. Likewise, it 
acts within the kidney to promote calcium reabsorption in the distal tubule via activation of 
parathyroid hormone [32]. Moreover, it also aids in the absorption of phosphorus, an essential 
mineral in bone maintenance [33, 34]. Recently, vitamin D has been recognized in the scientific 
community as an immunological, anti-inflammatory, and transcription-modulating molecule. In 
either mice or human trials, vitamin D has been linked to diminishing the effects or reducing the 
risk of various inflammatory states such as non-obese type 1 diabetes, multiple sclerosis, lupus, 
and inflammatory bowel disease [35-38].  Because of its diversity in human health, it is no 
surprise that serum vitamin D deficiency has been associated with early mortality, myocardial 
infarction, diabetes, various cancers, and obesity [39-42].  
  The binding of vitamin D3 to the vitamin D (VDR) receptor is necessary to produce the 
aforementioned biological effects. The VDR has a high affinity and specificity for the bioactive 
1,25(OH)2D3 ligand. The binding of the ligand and the receptor is required for action mediation 
in a variety of human tissues including osteoblasts, macrophages, pancreatic beta cells, smooth 
muscle, adipocytes, and epithelial cells [22]. Vitamin D3, also identified as 1,25(OH)2D3, is 
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understood to modulate gene expression via two mechanisms: the first being interaction of 
transcriptional promoter genes and the retinoid X receptor/VDR heterodimer and the second 
being posttranslational modifications from calcium flux induction. The former mechanism 
begins with the introduction of free 1,25(OH)2D3 to the cell. Free 1,25(OH)2D3 binds to the 
VDRs, which then become phosphorylated, resulting in a significant conformational change that 
closes the receptor, thereby activating it. Phosphorylated vitamin D receptors bind to retinoid X 
receptors and create a heterodimer complex that is able to activate or repress transcription at 
promoter genes after stabilization on DNA vitamin D response elements [43]. VDR mRNA 
expression has been identified in most human tissues, including osteoblasts, keratinocytes, 
smooth muscle, epithelial cells and white adipocytes, supporting the diverse effects of 
1,25(OH)2D3  signaling. 
One example of a non-classical role of vitamin D is in the immune system. It is 
understood that numerous adaptive and innate immunity cells express the vitamin’s receptor. 
Moreover, both macrophages and dendritic cells of the immune system posses the 1α-
hydroxylase enzyme, resulting in hydroxylation of 25(OH)D3 to yield bioactive 1,25(OH)2D3. 
When pattern recognition cells sense a pathogen, they signal for increased expression of both the 
vitamin D activating enzyme and VDR. Ligand binding elicits an immune response via 
transcriptional activation and/or repression of the target genes of the downstream signaling 
pathways [32]. 
There is also evidence to support the activity of the vitamin D/VDR complex in the 
vascular system. Similar to the immune system, both VDR and 1α-hyrdoxylase have been 
identified in cardiac myocytes, fibroblasts, and smooth muscles cells. Vitamin D deficiency in 
humans has been associated with congestive heart failure, peripheral vascular disease, and 
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coronary artery disease. Similarly, in mice, vitamin D deficiency and VDR deletion is associated 
with elevated blood pressure and hyperreninemic hypertension with cardiac hypertrophy, 
respectively [32]. In a rodent study, rats were infused with 800 ng/kg/min of angiotensin II for a 
14-day period. This resulted in elevated blood pressure, elevated cardiac interstitial fibrosis, 
myocyte hypertrophy, and increased expression of the hypertrophy-sensitive fetal gene program. 
Interestingly, concurrent treatment with 1,25(OH)2D3  analog, paricalcitol, ameliorated these 
cardiac effects [44].  
 These are just a few examples of the expansive involvement of both the vitamin D ligand 
and VDR in mediating human biology. The involvement of the vitamin D complex in adipose 
tissue will be further elucidated later.  
 
2.1.2 Dietary and Non-dietary Sources of Vitamin D  
Vitamin D can be found in a variety of animal products including liver, eggs, milk, 
cheese, mushrooms, and some saltwater fish. The American food supply is also fortified with 
vitamin D. Fortified products include: orange juice, yogurt, and some cereals. Additionally, 
vitamin D is created endogenously. Cholecalciferol can be synthesized in the skin and 
transformed to bioactive calcitriol through a series of biological processes [33].  
 
2.1.3 Vitamin D Metabolism and Transportation  
Out of the two forms of vitamin D, vitamin D2 (ergocalciferol) and vitamin D3 
(cholecalciferol), vitamin D3 is the only form that is found naturally in humans and animals due 
to the synthesis of vitamin D3 from 7-dehydrocholesterol in the skin upon ultraviolet B 
irradiation. When 7-dehydrocholesterol in skin is exposed to UVB it is transformed into 
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previtamin D3. Further structural transformations produce vitamin D3 (cholecalciferol), allowing 
for translocation from the skin to the blood stream. Upon admission into the blood stream, 
vitamin D3 is bound to α1-globulin, a vitamin D binding protein. Once cholecalciferol reaches 
the liver, it is hydroxylated by 25 hydroxylase (encoded by CYP27A1) to release 25-
hydroxycholecalciferol (25(OH)D3) into circulation. In the kidney, 25(OH)D3 undergoes further 
hydroxylation by 1α hydroxylase (encoded by CYP271B) to complete the conversion of 
cholecalciferol to bioactive calcitriol (1,25(OH)2D3) [33]. A variety of cytochrome P450 
enzymes, including 24-hydoxylase (encoded by CYP24A1), initiate the inactivation and 
degradation of vitamin D3  and its metabolites by forming calcitrioic acid [33, 45]. A visual 
schematic has been provided to illustrate the metabolism of vitamin D (Fig. 1).  
The genomic action of 1,25(OH)2D3 is mediated through the vitamin D receptor (VDR), 
which upon binding to 1,25(OH)2D3 forms heterodimer with retinoid X receptor (RXR) and 
binds with vitamin D3 response elements in the promoters of target genes to regulate the target 
genes transcription.  
 
2.1.4 Vitamin D and Energy Metabolism 
The effects of vitamin D on energy metabolism have been studied to some extent. The 
most pertinent research regarding the current hypothesis assesses the impact of vitamin D and the 
VDR complex on white adipocyte differentiation, function, and total cellular metabolism. 
There is evidentiary support for inhibition of 3T3-L1 cell differentiation by 1,25(OH)2D3 
[22, 46]. When treated with calcitriol, mRNA and protein expression of adipocyte marker gene 
PPARγ, C/EBPβ, and SREBP1 are dose-dependently down-regulated. Likewise, 1,25(OH)2D3 
has been reported to impair lipogenesis in preadipocyte cells by promoting expression of  insulin 
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induced gene 2 (Insig2), a gene encoded to block fatty acid synthesis by modulating the 
proteolytic activation of sterol regulatory element-binding proteins [47]. Moreover, up regulation 
of the VDR in the absence of calcitriol has been reported to inhibit adipocyte differentiation [22]. 
While these results paint a convincing picture of the suppressive effects 1,25(OH)2D3 on 
adipocyte differentiation of murine derived 3T3-L1 [27, 28], it has been reported that a similar 
dose of 1,25(OH)2D3 (i.e., 10-8 mM or 10 nM) actually promoted differentiation of human 
subcutaneous preadipocytes [29].  
In characterizing the molecular mechanisms by which vitamin D3/VDR suppresses 3T3-
L1 adipocyte differentiation, it was found that VDR mRNA expression reached a maximum 6 
hours after induction of white adipocyte differentiation [46]. Moreover, VDR nuclear proteins 
imperative for VDR function, showed exponential accumulation at 4 hours and reached 
maximum expression at 12 hours post induction [46]. These results suggest that the vitamin D 
system is active at the early stages of adipocyte differentiation [46, 48].   
The difference between liganded and unliganded VDR in hindrance of normal 
adipogenesis has also been noted [46]. The VDR siRNA transfected cells without calcitriol did 
not significantly reduce PPARγ [46] . However, in the presence of calcitriol, expression of 
PPARγ and C/EBPα, an essential transcription factor that works in concert with PPARγ in 
adipogenesis, were reduced in 3T3-L1 cells over expressing VDR, likely due to the blocking of 
the C/EBPβ pathway [46, 49]. Thus, liganded VDR seems to be the most potent inhibitor of 
white adipocyte differentiation by limiting lipid accumulation and diminishing the production of 
PPARγ and C/EBPα [22, 46, 49].  
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Additionally, the effects of vitamin D on thermogenesis of white adipocytes were 
reported [50]. With as low as 1 nM vitamin D, both basal and pharmacologically induced 
expression of uncoupling protein 2 (UCP2) were diminished whereas a specific agonist for the 
membrane vitamin D receptor (mVDR), 1α,25 dihydroxylumisterol 3 was unable to show the 
same effects. Nuclear VDR knockdown blocked the inhibition by 1,25(OH)2D3  whereas a 
specific mVDR antagonist, 1α,25-dihydroxyvitaminD3, was unable to prevent the 1,25(OH)2D3 
inhibition of UCP2 expression [51]. These results suggest that thermogenesis of WAT is 
negatively impacted by the vitamin D/VDR complex through its genomic action [51].  
To further study the role of the VDR as it relates to adipogenesis and metabolism in vivo, 
an aP2-hVDR transgenic mouse model was created to specifically over express hVDR in 
adipocytes [52]. It was found that mice over expressing hVDR had a greater body fat percentage 
than their wild type counterparts on the standard chow diet [52]. Likewise, transgenic mice on 
the high fat diet had a more significant weight gain than wild type mice on the high fat diet. 
Interestingly, transgenic mice exhibited elevated cholesterol compared to the controls but they 
did not have statistically significant non-esterified fatty acids or triglycerides [52]. Metabolism 
was also altered in the transgenic mice. Expression of carnitine palmitoyl transferase 1 and 2, 
hexokinase, pyruvate kinase, hormone sensitive lipase, adipose triglyceride lipase, and 
uncoupling protein were reduced in adipose tissue of transgenic mice, leading to impaired β-
oxidation, glucose metabolism, and lipolysis [52]. 
To further illuminate the effects of VDR in vivo, literary evidence suggesting that VDR 
null mice maintain a leaner phenotype is described [26]. Ablation of the VDR in vivo was 
associated with a lower body fat in male and female mice on a high fat diet. Interestingly, BAT 
in VDR null mice was less abundant than in wild type regardless of the diet.  However, null mice 
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were able to maintain better BAT cell morphology i.e., shape and appearance, with fewer lipid 
droplets than the wild type counterparts. On the high fat diet, leptin levels were decreased in 
VDR null mice. Moreover, oxygen consumption rates, CO2 production, and total energy 
expenditure were significantly higher in VDR(-/-) mice without significant changes in dietary 
intake or physical activity [26]. Together, these results suggest that VDR is a negative regulator 
of adipose energy expenditure. 
Yet another study demonstrated that VDR knockdown can modulate energy metabolism 
in vivo [53]. This particular research supports the idea that the VDR/vitamin D ligand is a key 
regulator in adipogenesis and glucose metabolism. These researchers compared body weight, 
abdominal WAT, leptin, and food intake in young VDR knockout mice and wild type mice on a 
C57BL6 background fed with a rescue diet. It was found that VDRKO mice weighed 
significantly less at 2, 4, and 6 months of age compared to their age matched wild type 
counterparts. They also found almost 50% more abdominal white fat in the wild type mice at the 
6th month. Not surprisingly at the 4 and 6 month check points, adipokine leptin was significantly 
reduced in mice lacking VDR. The food intake, measured in grams per day, was notably 
indifferent at the 2 and 4 month time points. Unexpectedly, VDRKO were actually consuming 
more food (g/day) at 6 months. To examine the effects of VDR ablation on interscapular BAT 
(iBAT), interscapular brown fat was isolated and weighed and no significant difference in iBAT 
mass was found.  
This same group of researchers chose to further research the effects of VDR elimination 
in a different strain of mice genetically prone to obesity and impaired glucose metabolism: CD1 
mice [53]. When comparing the CD1 WT to the CD1 VDRKO, CD1 VDRKO mice weighed less 
and had significantly less abdominal and subcutaneous fat mass. This held true even when the 
  11 
dietary fat was increased from 5% to 15%. Interestingly, unlike in the C57BL6 model, CD1 mice 
did show differences in iBAT mass. On both 5% and 15% dietary fat diets CD1 WT mice had 
larger amounts of iBAT than the CD1 VDRKO mice despite CD1 VDRKO mice consuming 
significantly more calories than their WT counter parts [53].  
When comparing the metabolic parameters including serum glucose, insulin, and 
triglycerides, not surprisingly, the CD1 mice fed a 5% fat diet showed higher glucose, insulin 
and triglycerides than the C57BL6 mice. However, in both CD1 and C57BL6 VDRKO models, 
glucose, insulin, and triglycerides were normal. This suggests that even in cases of genetic 
obesity, VDRKO can protect against metabolic abnormalities [53]. 
The next question raised is whether or not CYP27B1 ablation, the enzyme required for 
1,25(OH)2D3 synthesis, produces any remarkable changes. On both the 5% and 15% fat rescue 
diets, CYP27B1 KO mice were lighter than the wild types with smaller abdominal adipose tissue 
stores. Like the VDRKO mice, CYP27B1KO mice were hypoleptinemic, hyperphagic, and had 
exhibited no differences in iBAT [53].  
 To elucidate the mechanism by VDR modulates the lean phenotype, researchers 
measured mRNA expression of PPARγ and fatty acid synthase (FAS) and found that neither 
PPARγ nor FAS were significantly different between knockout and wild type mice. In contrast, 
they noted that UCP1 mRNA was 25 fold higher in the WAT of VDRKO than in that of wild 
type mice. These results suggest that VDR may negatively modulate energy expenditure through 
suppression of UCP1 in WAT, leading to a lean phenotype in VDR null mice [53].  
 Taken together, these studies suggest the significant impact of vitamin D and/or VDR on 
the development of BAT and WAT and whole body energy metabolism. 
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2.2 Brown Adipose Tissue: Significance and Nutritional Regulation  
2.2.1 Brown Adipose Tissue Function 
Brown adipose tissue (BAT) has been identified as a highly vascularized thermogenic 
tissue responsible for non-shivering, adaptive thermogenesis during cold exposure [54, 55]. It is 
a multilocular tissue because its cells are composed of many small lipid droplets dispersed in the 
cytosol surrounding a central nucleus. It also contains a high number of mitochondria, the 
organelle responsible for the generation of heat that occurs in these cells. In contrast, WAT is 
unilocular with a singular lipid droplet, few mitochondria, and peripheral nucleus. White adipose 
tissue is much less metabolically active than BAT because its major function is triglyceride 
storage [56].  
Brown adipose tissue’s thermogenic capacity is conferred by its expression of UCP1, 
which is confined to the inner mitochondrial membrane. Under activation of the sympathetic 
nervous system UCP1 enhances energy expenditure by uncoupling oxidative phosphorylation 
from ATP synthesis [55]. Normally, the process of the electron transport chain’s (ETC) oxidative 
phosphorylation produces free energy that drives adenosine triphosphate (ATP) synthesis. The 
proton gradient produced by the oxidation-reduction reactions of the ETC is utilized by ATP 
synthase converting adenosine diphosphate (ADP) to ATP. Therefore, the respiratory capacity of 
a cell is limited by the efficiency of mitochondrial phosphorylation of ADP to ATP. In brown 
adipocytes, the transmembrane protein UCP1 creates a proton leak, uncoupling these processes 
and consequently, generates heat. This process allows for continuation of fatty acid oxidation 
with a low rate of ATP synthesis [57, 58]. It has also been suggested that glucose is more highly 
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metabolized via anaerobic glycolysis in BAT to compensate for the impaired ATP synthesis of 
the ETC [58]. 
Previously, BAT was believed to be present in infants only.  Because infants have 
minimal skeletal muscle for shivering, BAT was presumed to be the mechanism by which infants 
maintained temperature homeostasis. Approximately 2-4% of the birth weight can be attributed 
to BAT. However, at about one month after birth, brown adipose tissue is significantly reduced 
[59].  BAT degeneration is a result of apoptosis induced by tumor necrosis factor alpha [60]. 
With the use of Positron Emission Tomography associated with Computed Tomography (PET-
CT), researchers have located depots of BAT in adults [7-11, 61].  Radioactive glucose analogue 
18F-flurodeoxyglucose (FDG) is traditionally used to identify tissues with glycolytic activity in 
PET scans. Intravenous administration of the analogue unintentionally discovered depots of BAT 
in adult humans due to its unsuspected uptake of FDG [62]. Currently, FDG uptake is the gold 
standard in measuring BAT [55]. The largest depots of this metabolically active tissue can be 
found in the: supraclavicular, suprarenal, paravertebral (interscapular), and neck regions [21, 61, 
63]. Statistical analyses have indicated that, in humans, BAT is negatively correlated with 
outdoor temperature and age. Furthermore, women have greater BAT mass and glucose uptake 
than men; though, this disparity between the two genders seems to diminish as age increases 
[21].  
 
2.2.2 Brown Adipose Development 
In white adipogenesis, cellular differentiation begins with rapid expression of 
transcription factors CCAAT/enhancer-binding protein β (C/EBPβ) followed by C/EBPα, 
PPARγ, and sterol regulatory element-binding protein 1 (SREBP1). The upregulation of these 
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proteins results in the development of an adipocyte phenotype, as evidence by adipogenic 
enzyme markers such as lipoprotein lipase and fatty acid synthase [22]. It has been reported that 
in normal 3T3-L1 differentiation, VDR is also expressed in the early stages of differentiation and 
is maintained in the presence of 1,25(OH)2D3 [22].  
Classical brown adipocytes are derived from Myf5-positive myoblastic cells [58, 60]. 
The development of brown adipocytes is controlled largely by transcription factor PPARγ and 
transcriptional coactivator, PPARγ coactivator 1α (PGC1α).  
PGC1α is responsible for the promotion of UCP1 expression by interacting with PPARγ 
and RXR heterodimer, allowing for transcription of genes involved in mitochondrial oxidative 
phosphorylation and UCP1 expression.  Likewise, mitochondrial biogenesis relies on PGC1α for 
nuclear respiratory factor induction (Nrf-1). Nrf-1 is responsible for inducing the expression of 
the genes of the electron-transport chain. Not surprisingly, PGC1α is expressed at higher levels 
in BAT than in WAT and is up regulated following cold exposure and β adrenergic stimulation 
via the p38 MAPK pathway [64].  
When ectopic expression of PGC1α is permitted in WAT, they adopt a phenotype similar 
to brown adipocytes, expressing UCP1 [19, 65]. Moreover, fatty acid metabolism enzymes in 
WAT increase with PGC1α expression, suggesting the potential for advanced fatty acid 
metabolism in browning white adipocytes [65]. Some research suggests the necessary 
involvement of zinc finger containing protein PR domain containing 16 (PRDM16) in 
conjunction with PGC1α, PPARγ, and C/EBPβ in the browning of white preadipocytes via 
promotion of thermogenic and brown adipogenic gene expression [16, 17, 66]. 
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PRDM16 is involved in both BAT and WAT development by simultaneously inhibiting 
the expression of WAT genes via transcriptional corepressors and promoting the expression of 
BAT genes through interaction with PGC1α [67, 68]. BAT gene expression is enhanced by 
PPARγ stabilization of PRDM16 on the promoter regions of BAT specific genes [17, 67, 69].  
A number of cell types have been identified as having potential to adopt a brown 
phenotype, contributing to uncoupling and thermogenesis. There is some evidence to suggest that 
human subcutaneous tissue contains a distinctly different beige adipocyte precursor cells that are 
identified by expression of genes CITED1 and CD137 [70]. While these cells express typical 
WAT genes, they have a unique capacity to also express UCP1. These cells, when appropriately 
stimulated with PPARγ agonists, can differentiate into functional beige or brown adipocytes. 
Interestingly, subcutaneous adipose tissue samples from obese individuals had impaired UCP1 
gene and protein expression when compared to the lean individuals. These data suggest 
incapacity of BAT in obese individuals to function maximally [70]. 
Human multipotent adipose-derived stem cells (hMADs), with prolonged exposure to 
PPARγ, are able to differentiate into functional brown adipocytes, characterized by their 
expression of UCP1 and Cidea [71].  Thyroid hormone triiodothyronine may also have the 
capacity to promote the browning of hMADS. In one study, the introduction of triiodothyronine 
to hMADS resulted in elevated expression of the following thermogenic genes: UCP1, PGC1α, 
NRF1, TFAM, Cidea, and Elovl [72]. Subsequently, oxygen consumption rates were 
significantly increased in triiodothyronine treated groups, suggesting enhanced mitochondrial 
biogenesis [72]. 
Muscle derived CD34+ cells are another potential progenitor cell with the ability to 
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express a brown adipocyte phenotype [73]. One study utilized tissues extrapolated from humans 
(adult and fetal) as well as mice for examination.  A variety of skeletal muscle cells were 
identified during the course of this study; interestingly, the CD34+ cells of expanded fetal 
muscles showed gene expression similar to that of brown adipocytes.  Upon further investigation 
with RT-PCR, it was found that differentiated skeletal muscles expressing the CD34+ protein on 
the cell surface demonstrated UCP1, PPARγ, PGC1α, β3-adrenoreceptor, and Cidea mRNA 
expression.  A second finding of this study was that CD34+ cells’ UCP1 expression could be up 
regulated by exposure to pharmacological treatment.  UCP1 mRNA was increased approximately 
seven to eightfold by cAMP derivatives in both primary culture and expanded cells. 
Interestingly, PPARγ agonist rosiglitzone proved to create an eightfold increase in expanded 
cells but yielded no statistically significant change in primary culture cells. The reason for this 
incongruity is unknown. These findings suggest that CD34+ cells in fetal muscle tissues have the 
capacity to express UCP1 and develop into functional brown adipocytes provided proper 
stimulation [73]. 
Lastly, adipocyte-like skin dermal cells from individuals with Hereditary Vitamin D 
Resistant Rickets (HVDRR) have been examined for their capacity to brown [74]. In this 
particular study, UCP1 expression was increased in the skin dermal cells from HVDRR 
individuals when compared to the controls [75]. The study also revealed that the suppression of 
UCP1 mRNA by VDR appeared to be mediated by a negative response element found in the 
proximal region of the human UCP1 promoter [75]. It is apparent from this study that the 
vitamin D/VDR complex suppresses the browning process, at least in this specific tissue.  
The ability to convert white adipocytes or to manipulate stem cells to result in 
hyperplasia of brown adipocytes is crucial to the concept of stem cell treatment of obesity and 
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metabolic syndrome. Transplantamtion of BAT has shown to markedly improve glucose 
metabolism and insulin resistance in mice [15, 76]. If these findings can be repeated in humans, 
there is opportunity to ameliorate obesity related disease with therapeutic BAT tissue. 
 
2.2.3 Brown Adipose Tissue Activation 
 BAT is richly innervated by sympathetic nervous system efferent fibers. The release of 
noradrenaline from these fibers enhance both the thermogenic activity, via UCP1 activity, and 
heat production, which involves BAT cell proliferation, mitochondriogenesis, and UCP1 
expression [77]. The role of β3 adrenergic receptors has been particularly well characterized in 
BAT.  These receptors are found on the cell surface of mature brown fat cells and are stimulated 
by norepinephrine as part of a sympathetic nervous system reaction.  The stimulation results in 
the induction of an intracellular pathway activating cyclic adenosine monophosphate (cAMP), 
protein kinase A, hormone sensitive lipase, lipid oxidation, and downstream kinases and 
transcriptional factors that mediate UCP1 thermogenic activity [16, 78, 79].  Activation of 
lipolysis in this process results in degradation of fatty acids mobilized from intracellular 
triacylglycerol stores and the systemic circulation conferring the lipid regulatory effect of BAT 
[14, 80]. The Rothwell and Stock calculation estimated that an average human male expending 
approximately 2500 kcal/day could yield an increase in energy expenditure (EE) by 10-20% 
provided proper stimulation of 40-50 g of BAT. Some researchers support the Rothwell and 
Stock calculation by reporting EE increases of 11-34% but other researchers hypothesize and/or 
report a much more conservative number of 2-5% of total EE [70]. 
It is well understood that brown adipose tissue is activated by cold exposure. A number 
of studies report enhanced BAT activity with as little as two hours of cold exposure in both 
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human and mouse models. One theory suggests that cold stimuli produces vascular endothelial 
growth factor expression of which yields angiogenesis. This angiogenesis in BAT is associated 
with BAT hyperplasia [58]. Another theory suggests that transient receptor potential channels 
(TRP) are responsible for receiving the cold stimuli and inducing thermogenesis via the 
aforementioned β3 adrenergic mechanism. It has been established that these TRPs receive 
stimuli from chemical compounds as well. 
 
2.2.4 Regulation of Brown Adipose Mass by Nutritional and Non-nutritional Factors 
A variety of nutritional and non-nutritional regulators have been identified in the 
development and activation of brown adipose mass. These factors encourage the activation of 
brown adipose tissue, promote the browning of white adipose tissue, or work to achieve both 
activation and development.  
For example, BAT can be activated by various capsinoid analogues like capsaicin found 
in chili peppers. These compounds increase thermogenesis via the TRPs and β3 adrenergic 
mechanisms [58]. Moreover, ephedrine [81], caffeine[82], catechin polyphenols[83], and 
medium-chain triglycerides [84] have also demonstrated β3 adrenergic stimulating or UCP1 
stimulating activity [81-85]. Utilization of these dietary compounds has been effective in 
increasing energy expenditure ranging from 4 to 8% of the total 24-hour energy expenditure 
[55]. However, is important to note that these particular compounds have alternative properties 
that may contribute to body composition changes aside from UCP1 stimulation like appetite 
suppression, fat absorption inhibition, and promotion of physical activity [55]. 
Other dietary factors known to activate brown adipose tissue include dietary methionine 
and leucine restriction, fucoxanthin, conjugated linoleic acid, and omega 3 fatty acids [86]. Some 
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of these aforementioned dietary factors are also capable of stimulating the browning of white 
adipose tissue.  
Both methionine and leucine restriction diets result in the activation of brown adipose 
tissue. Mice deprived of these essential amino acids experience increased UCP1 induction and 
β3-adrenergic signaling. The data strongly supports the relationship between methionine and 
leucine deprivation and weight regulation. It is hypothesized that methionine deprivation 
increases energy expenditure by accelerating β-adrenergic receptor signaling. Leucine 
deprivation is thought to reduce fat deposition and support fat loss via activation of BAT and the 
subsequent catabolism of fatty acids [87-89]. Conversely, there is evidence to suggest that 
leucine supplementation, rather than deprivation, is beneficial in vivo. Supplementation with 
leucine increased mitochondrial mass and oxygen consumption rates which yielded weight loss 
or diet-induced obesity resistance [90].  
Fucoxanthin, a carotenoid found in brown algae and seaweed extract, has been identified 
as a nutritional agent of increasing UCP1 and lipid catabolism proteins at both the mRNA and 
protein expression levels in white adipocytes but not brown adipocytes. Moreover, fucoxanthin 
metabolites appear to enhance WAT β3-adrenergic receptor production, increasing sensitivity to 
sympathetic nerve signaling. There is also evidence to suggest that activation of AMPK, fatty 
acid β-oxidation, and lipogenesis results from the presence of fucoxanthin. The specific 
mechanisms for the metabolite effects on WAT browning have yet to be elucidated [91-95].  
Like fucoxanthin, 2-hydroxyoleic acid, a synthetic olive oil analog, was able to induce 
UCP1 expression in white adipose tissue selectively. Likewise, this analog has been shown to 
enhance the cAMP/PKA pathway, resulting in the browning of white adipose tissue. Oral 
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supplementation with natural olive oil reportedly increases expression of all uncoupling proteins 
and promotes escalated total body oxygen consumption [96-100]. 
The trans-10, cis-12 isomer of conjugated linoleic acid (CLA) has shown marked adipose 
reduction in variety of species by increasing WAT apoptosis, decreasing differentiation and 
lipogenesis of adipocytes, and increasing fatty acid oxidation. Research has also described the 
ability of CLA to increase brown phenotypic genes including UCP1, PGC1α, and Cidea in WAT 
specifically [101-103].  
Lastly, omega 3 fatty acids have shown the capacity to mediate adipose function and 
growth by both up-regulation of UCP1 and WAT oxidation [104, 105]. Alternately, another 
study found that just marginal amounts of EPA and DHA in the daily diet, comprising just 15% 
of daily dietary fats, can increase β-oxidation in conjunction with the up-regulation of other 
PGC1α, CPT1, and Nrf1 but not UCP1 genes in WAT [106].  
 Various non-nutritional regulators are also key in promoting the development and 
activation of brown adipose tissue [58]. For example, exercise acts as a non-nutritional regulator 
resulting in the browning of white adipose tissue. It is said to increase the expression of Irisin, a 
PGC1α dependent myokine that induces the browning of white adipose tissue [58]. This 
phenomenon may contribute to the overall effect of regular exercise on increasing basal 
metabolic rate. 
Other identified non-nutritional regulators of browning include: cyclooxygenase-2, 
receptor interacting protein 140, liver X receptor α, bone morphogenetic protein 7, fibroblast 
growth factor 21, and retinoblastoma protein among others [86].  
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2.3 The Research Gap 
In summary, the existing research exploring the role of vitamin D3 in total energy 
metabolism is contradictory and inconclusive. In vitro white adipocyte study results would 
suggest that vitamin D3 impairs growth by inhibiting the production of its major regulators 
PPARγ and C/EBPα. Conversely, the in vivo data would suggest that vitamin D3 promotes WAT 
differentiation and growth because VDR ablation decreased body fat [26] while VDR over 
expression increased body fat [52].  
The effect of vitamin D3 on adipose differentiation and function has only been studied in 
WAT. The purpose of this thesis is to characterize the effect of both over expression of the VDR 
and an over abundance of vitamin D3 in brown adipose differentiation and mitochondrial 
respiration. A characterization of the effects of vitamin D3 on brown adipocytes will provide a 
better understanding of the environment in which BAT grows and functions optimally. To 
measure the effect of vitamin D3 on differentiation the following methods were used: mRNA 
expression was to quantify specific gene expression, Oil Red O stain to determine the change in 
lipid accumulation, MitoTracker to quantify mitochondrial content, and western blot to detect 
proteins. To measure the effect of vitamin D3 on mitochondrial respiration, a mitochondrial stress 
test was conducted and analyzed.  Lastly, a luciferase assay was used to determine changes in 
PPARγ transactivation under the influence of both the vitamin D3 ligand and overexpression of 
VDR.  
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CHAPTER III 
Materials and Methods 
 
3.1.1 Reagents 
 
Vitamin D3, 1,25(OH)2D3, was purchased from Enzo (Farmingdale, NY). 3-isobutyl-L-
methylxanthine, T3, dexamethasone, insulin, and indometacin were purchased from Sigma-
Aldrich (St. Louis, MO).  
 
3.1.2 Animals  
The mice studies were approved by the Institutional Animal Care and Use Committee at 
the University of Tennessee. Diet-induced obesity (DIO) mice, genetically obese ob/ob (leptin 
deficient) mice, and their respective controls have been described elsewhere[107]. Briefly, the 
mice were purchased from the Jackson Laboratory (Bar Harbor, ME). For DIO study, 6-week old 
male C57BL/6J mice (n=7 per group) were fed with either a high-fat diet (60% Kcal from fat, 
Research Diets Inc., New Brunswick, NJ) (DIO group) or chow diet (Chow group) for 20 weeks 
before sacrificed at 26 weeks of age. For ob/ob mice study, 6-week old male ob/ob (Ob/ob 
group) and their control wild type mice (Wt group) (n=6 per group) were fed with chow diet for 
8 weeks before sacrificed at 14 weeks of age. Upon sacrifice, interscapular BAT was removed 
and immediately snap frozen in liquid nitrogen and stored at -80 °C until analysis. 
 
3.1.3 Brown fat cell culture and differentiation  
Murine brown fat cell line is a gift from Dr. Johannes Klein (University of Lubeck, 
Lubeck, Germany), who has generated the cell line from interscapular brown fat of newborn 
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C57BL/6 mice[108]. Brown fat cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 20% fetal bovine serum (FBS, Atlas Biologicals, Fort Collins, CO) 
at 37°C humidified atmosphere of 5% CO2 in air, until they reached confluence (designated as 
day 0 or D0). The cells were then induced to differentiate by the induction media containing 
DMEM supplemented with 20% FBS, 1 nM T3, 20 nM insulin, 0.125 mM indometacin, 5 µM 
dexamethasone, and 0.5 mM 3-isobutyl-L-methylxanthine for 24 hr, followed by changing into 
the differentiation media containing DMEM supplemented with 20% FBS, 1 nM T3, and 20 nM 
insulin every two days until fully differentiated on day 6 (D6). For the study of 1,25(OH)2D3 on 
brown adipocyte differentiation, 1,25(OH)2D3 (1, 10, 100 nM) or the vehicle control DMSO was 
added at D0, and replaced with each change of the media during the differentiation process, or 
otherwise as indicated in the figure legends. For the study of VDR over expression, Myc-DDK 
tagged murine VDR expression plasmid (OriGene, Rockville, MD) was transfected into brown 
preadipocytes for 72 hr and the stably transfected cells were selected by antibiotics (G418) for 3 
weeks. The exogenous VDR expression was confirmed by mRNA and protein expression. 
 
3.1.4 Western Blot Analysis  
 
 Total cell lysates were prepared and protein concentrations were determined by BCA 
assay kit (Thermo Scientific, Waltham, MA). Thirty micrograms of total cell lysate was 
subjected to 10% SDS-PAGE and transferred to polyvinylidene difluoride membrane (Bio-Rad, 
Hercules, CA). The membrane was blocked with 20 mM Tris-HCl, 137 mM NaCl, and 0.1% 
Tween 20 (pH 7.4) containing 5% nonfat milk. The membrane was immunoblotted with primary 
antibodies at 4 °C for overnight followed by secondary antibody conjugated with horseradish 
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peroxidase (GE Healthcare, Pittsburgh, PA). The signal was quantified by densitometry using a 
ChemiDocXRS+ imaging system with ImageLab software (Bio-Rad). 
 
3.1.5 RNA preparation and quantitative real time PCR analysis  
 
Total RNA was prepared using TRI reagent (Molecular Research Center, Cincinnati, OH) 
according to the manufacturer’s instructions. Total RNA abundance was quantified using a 
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). Reverse 
transcription was carried out using Fermentas first strand synthesis kit (Thermo Scientific, 
Pittsburgh, PA) according to the manufacturer’s instructions. mRNA expression of indicated 
genes and the house keeping 36B4 were measured quantitatively using Absolute Blue QPCR 
SYBR Green ROX mix (Thermo Fisher Scientific) and gene specific primers (primer sequences 
available upon request). PCR reactions were run in a 96-well format using an ABI 7300HT 
instrument. Cycle conditions were 50 0C for 2 min, 95 0C for 15 min, then 40 cycles at 95 0C for 
15 s/60 0C for 1 min. Relative gene expression was calculated using the 2-ΔΔCt method, which 
normalizes against 36B4. 
 
3.1.6 MTT Assays   
The assays for measuring cell viability were performed according to the manufacturer's 
instructions. Briefly, the brown preadipocytes were seeded into 24-well plates. When reached 
confluency, they were induced to differentiate according to the procedures described above in the 
presence or absence of Vit D3 (1, 10, 100 nM) for 24 hr, 48 hr, and 5 days. At the end of the 
indicated times, 50 µL of MTT (5 mg/mL) was added to each well and the plate was incubated at 
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37 °C for 3 hr. Purple formazan crystal was solubilized by addition of 100 µL isopropanol. 
Absorbance was measured at a test wavelength of 570 nm and a reference wavelength of 650 nm 
using GloMax-Multi Detection System. 
 
3.1.7 Analysis of mitochondrial content by MitoTracker green staining 
Mitochondrial contents were labeled using mitochondria-specific dye MitoTracker Green 
(Life technologies, Carlsbad, CA) according to manufacturer’s protocol. Briefly, the 
differentiated brown adipocytes were washed and trypsinized from the cultured plate and 
incubated with mitoTraker green at 100 nM for 30 min at 37 0C. The fluorescence intensity was 
measured with Accuri C6 flow cytometry (BD, Franklin Lakes, NJ). Background 
autofluorescence from non-stained cells were averaged and subtracted from the mean 
fluorescence intensity values. Relative fluorescence intensity is the fold of the mean fluorescence 
intensity of the controls. 
 
3.1.8 Reporter Gene Assays  
Brown preadipocytes were transiently transfected with PPARγ transactivation reporter 
system [109], in which murine PPARγ ligand binding domain is coupled to the Gal4 DNA 
binding domain to form mPPARγ-Gal4 and a reporter construct containing an upstream 
activating sequence (UAS)–linked luciferase, 4xUAS-TK-luc (TK: thymidine kinase) and β-
galactosidase expression plasmid. PPARγ transactivation system was a gift from Dr Susanne 
Mandrup at University of Southern Denmark, Denmark. The cells were then pre-treated with 
increasing doses of 1,25(OH)2D3 (1, 10, 100 nM) or the vehicle control DMSO overnight and 
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then co-treated with or without PPARγ ligand rosiglitazone (1 µM) for 8 hr. In the VDR over 
expression study, PPARγ transactivation system and β-galactosidase expression plasmid were 
co-transfected with murine VDR expression plasmid or the vector plasmid for 24 hr. The cells 
were then treated with or without PPARγ ligand rosiglitazone for 8 hr. The cell lysate was 
prepared and reporter luciferase and β-galactosidase activities were measured with GloMax 
Luminometer (Promega, Madison, WI). Relative luciferase activities were normalized by β-
galactosidase activities and expressed as fold of the vehicle control. 
 
3.1.9 Cell respiration measurements  
5x104 brown adipocytes (D6) that have been treated with or without 1, 25(OH)2D3 (1, 10, 100 
nM) were sub-cultured in 24 well XF assay plates overnight in the differentiation medium and 
subjected to real-time measurements of oxygen consumption (OCR) and extracellular 
acidification of the medium (ECAR) using XF24 Extracellular Flux Analyzer (Seahorse 
Biosciences, North Billerica, MA). Cells were rinsed once, changed to 500 µl of XF assay buffer 
(DMEM without NaHCO3, containing 10 mM glucose, 2 mM pyruvate, 2 mM GlutaMAX, pH 
7.4), and equilibrated at non-CO2 incubator and 37 0C for 1hr. Following the basal measurements 
of OCR and ECAR, all cells were injected with isoproterenol (1 µM) and subsequent readings 
were taken over a 6 hr-period. For mitochondrial stress tests, mitochondrial complex inhibitors 
were injected to all treatments sequentially in the following order: oligomycin (1 µM), FCCP 
(0.75 µM), antimycin A/rotenone (1 µM each), and 3 readings were taken after each inhibitor. 
OCR and ECAR were automatically recorded by XF24 software v1.8 provided by the 
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manufacturer. Calculations of maximal OCR, OCR from ATP generation, and from proton leak, 
and spare respiration capacity were performed according to the manufacturer’s instructions.  
 
3.1.10 Statistical Analysis   
Statistical analysis was performed using SigmaPlot 11.0 (Systat Software, Inc.). One way 
ANOVA with repeated measures followed by multiple comparisons test (Student-Newman-
Keuls Method) were performed to determine the differences among the treatment groups (e.g., 
doses) and/or time points (e.g., D0-D6). Student’s t-tests were performed when appropriate. Data 
were Log transformed when appropriate. The level of significance was set at p< 0.05. 
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CHAPTER IV  
Results and Discussion 
4.1 Results  
 
4.1.1 VDR, CYP24A1 and CYP27B1 mRNA expression in the BAT of mice model of 
obesity and during brown adipocyte differentiation in vitro 
First, mRNA expression of VDR, vitamin D3 activating enzyme 1α-hydroxylase 
CYP27B1, and degrading enzyme 24-hydroxylase CYP24A1 in the interscapular BAT of both 
diet-induced obesity and genetically obese ob/ob (leptin deficient) mice was examined. 
Expression of UCP1 mRNA was significantly lower in the BAT of ob/ob mice when compared 
to the wild type counterpart (p<0.05) (Fig. 2A). The mRNA of both VDR and CYP27B1 in the 
BAT of ob/ob were not statistically significant. In the DIO mice model of obesity, no significant 
changes were seen in mRNA levels of VDR, CYP27B1, and UCP1. Levels of CYP24B1 mRNA 
were undetectable by q-PCR (Fig. 2B).  
 
4.1.2 Effects of 1,25(OH)2D3 on the vitamin D system during brown adipocyte 
differentiation 
To study the vitamin D3 system in brown adipocyte differentiation, an immortalized 
brown fat cell line generated from the classical interscapular BAT from C57BL/6 mice [108] was 
utilized and mRNA expression of VDR, CYP27B1, and CYP24A1 during the differentiation 
process was examined. VDR mRNA expression was induced by the induction treatment at day 1 
(D1), and gradually decreased to less than 10% of the D0 level (Fig. 3A). A similar mRNA 
profile of induction at D1 and subsequent decrease was seen in CYP24A1 (Fig. 3B). The 
induction treatment did not result in induction of CYP27B1; however, its expression was 
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diminished from the basal rate by the end of differentiation (Fig. 3C). The results suggest that 
vitamin D3 system is down-regulated in brown adipocyte differentiation. 
 
4.1.3 Effects of 1,25(OH)2D3 on brown adipocyte lipid accumulation, mRNA expression, 
and mitochondrial content 
Brown preadipocytes were differentiated under the vehicle control DMSO or under 
conditions described in materials and methods with variable doses of 1,25(OH)2D3 (1, 10, or 100 
nM) for seven days (D0-D6) (Fig. 4A top). Cell viability (MTT) assays indicated that 
1,25(OH)2D3 did not affect cell viability when treated up to 100 nM for up to 5 days (data not 
shown). The ORO stains reflect dose-depended suppression of brown adipocyte lipid 
accumulation by 1,25(OH)2D3 (Fig. 4A-C).  
Moreover, the data shows a dose dependent suppression in mRNA expression of brown 
adipocyte markers peroxisome proliferator activator receptor gamma (PPARγ), peroxisome 
proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1α), uncoupling protein 1 
(UCP1), nuclear respiratory factor 1 (Nrf-1), cell-death inducing DFFA-like effector a (Cidea), 
and nucleus encoded mitochondrial gene, cytochrome c oxidase subunit IV a (Cox4a) (Fig. 4D). 
1,25(OH)2D3 degrading enzyme CYP24A1 mRNA was dose-dependently up-regulated, 
validating the presence of 1,25(OH)2D3  in the treatment due to the understanding that increased 
1,25(OH)2D3 yields an increase in its degrading enzyme to dispose of it (Fig. 4D). It should be 
noted that during the course of the differentiation, the most suppressive effects of calcitriol were 
seen at D4 and either diminished slightly or plateaued at D6. Thus, D4 will be the time point 
used in the subsequent VDR experiments. Protein expression of PPARγ, PGC-1α, and UCP1 
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confirmed 1,25(OH)2D3’s dose-dependent effects on mRNA expression during differentiation 
(Fig. 4E). 
With the understanding that 1,25(OH)2D3 treatment inhibits mRNA expression of PGC-
1α, the master regulator of mitochondrial biogenesis, and other mitochondrial genes, such as 
Nrf-1, Cox4a we chose to further explore the impact on mitochondrial biogenesis. To confirm or 
deny that reduction in gene expression resulted in impaired mitochondrial biogenesis, we 
employed mitochondrial specific fluorescence dye mitoTracker green to measure mitochondrial 
content, i.e. number of mitochondria. Consistent with the mRNA results, 1,25(OH)2D3 
significantly suppressed mitochondrial content on D4, but not on D6 (Fig. 4F).  
 
4.1.4 Brown adipocyte time sensitivity to 1,25(OH)2D3 treatment 
To better understand time sensitivity of 1,25(OH)2D3 treatment, we differentiated brown 
preadipocytes in the presence of 1,25(OH)2D3, either starting from day 0 (Day 0-6), day 3 (Day 
3-6) or from day 5 (Day 5-6). The full 7 day treatment resulted in the most significant 
suppression on differentiation, compared to those of Day 3-6 and Day 5-6 treatment (Fig. 5A). 
The next time sensitivity experiment measured differentiation of brown preadipocytes 
with1,25(OH)2D3 for an allotted time frame, being introduced and removed at different stages of 
differentiation. When 1,25(OH)2D3 was not present, cells were provided standard media. The 
Day 0-1 and Day 0-2 treatments resulted in a similar level of suppression to that of the full Day 
0-6 treatment from the previous experiment. The Day 3-4 or Day 5-6 treatments were ineffective 
in attenuating differentiation (Fig. 5B). These data suggest that first days of differentiation (Day 
0 to Day 2) are the most sensitive to 1,25(OH)2D3 treatment. 
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4.1.5 Effects of 1,25(OH)2D3 on mitochondrial respiration in brown adipocytes  
To confirm the functional consequences of the effect of vitamin D3 on brown adipocyte 
differentiation, we examined mitochondrial respiration in 1,25(OH)2D3 treated brown adipocytes 
by measuring cellular bioenergetics coupled with mitochondrial stress tests using a XF24 
Extracellular Flux Analyzer (Fig. 6A-B).  Isoproterenol-stimulated oxygen consumption rates 
(OCR) (Fig. 6C), maximal OCR (Fig. 6D), and OCR from proton leak (Fig. 6F) were 
significantly impaired by 1,25(OH)2D3 in concentrations as low as 1 nM (p<0.01). However, 
1,25(OH)2D3 treatment did not impact ATP-generating OCR (Fig. 6E) and spare respiration 
capacity (Fig. 6G) even at the highest concentration.  
 
4.1.6 Effects of over-expression of VDR on brown adipocyte differentiation   
Since our preliminary experiments showed down-regulation of VDR during 
differentiation we chose to artificially increase VDR, employing a stable transfection of murine 
VDR expression plasmid into the brown preadipocytes. Measurements were taken at day 4 of 
differentiation because this time point seemed to be the most influenced by the vitamin D system 
as evidenced by the previous mRNA study (Fig 4). Pooled VDR transfected brown 
preadipocytes, in the absence of 1,25(OH)2D3, showed a two-fold increase in mRNA expression 
of VDR, which correlated to a ~ten-fold mRNA expression of CYP24A1 when compared vector-
transfected pool cells (Fig. 7A). Conversely, VDR over-expression yielded no change of 
CYP27B1 mRNA compared with the control (Fig. 7A). VDR over-expression suppressed 
mRNA expression of the brown adipocyte markers UCP1 (Fig. 7B), PGC-1α (Fig. 7C), and 
PPARγ (Fig. 7D) at basal (D0) and D4 in the differentiation process. These results are consistent 
with the effects of 1,25(OH)2D3 treatment in the aforementioned experiments. 
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4.1.7 1,25(OH)2D3/VDR suppresses PPARγ  transactivation in brown preadipocytes   
As described previously, PPARγ transactivation is necessary for successful 
differentiation of brown preadipocytes into mature, functional adipocytes.  To fully understand 
the mechanism by which 1,25(OH)2D3/VDR suppresses differentiation, we measured PPARγ 
transactivation via reporter assays. Treatments of 1, 10, and 100 nm of 1,25(OH)2D3 dose-
dependently suppressed both basal and PPARγ ligand rosiglitazone (Rosi, 1µM)-induced PPARγ 
transactivation (both p<0.05 for the trend) (Fig. 8A). Consistently, Rosi-induced PPARγ 
transactivation in VDR transgenic mice was similarly suppressed (p<0.05) (Fig. 8B).  
 
4.2 Discussion 
 
Accumulating evidence suggests the critical involvement of the vitamin D3 system in 
energy metabolism. The majority of existing studies evaluate the effects of vitamin D3 on 
adipogenesis and lipid metabolism in white adipose tissue, and/or white adipocytes [110]. In the 
ob/ob mouse model, UCP1 was significantly decreased (Fig. 2A). However, neither VDR and 
CYP27B1 were altered (Fig. 2A). Similarly, in the diet induced obesity mouse model, mRNA of 
UCP1, CYP27B1, CYP24A1 expression were not significantly different from that of the chow-
fed mice (Fig. 2B). The current research indicates mixed effects of diet-induced obesity on UCP1 
expression. Excessive caloric intake resulting in obesity has been associated with increases, 
decreases, and no effect on UCP-1 expression [111]. The impaired UCP1 mRNA expression in 
the BAT of ob/ob mice of the current study lead to inquisition about the potential correlation 
between obesity and an impaired energy metabolism due to reduced BAT efficiency. The 
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vitamin D/VDR complex was explored for its potential to either ameliorate or exacerbate BAT 
differentiation and function because of its previously identified relationship with WAT.  
 Potential mechanisms underlying altered energy metabolism in VDR knockout mice [26] 
and transgenic mice with adipose-specific over-expression of VDR have been elucidated [52]. 
To recap, such mechanisms include altered UCP1 expression and modified metabolic markers 
such as adiponectin and insulin. The results demonstrate the effects of 1,25(OH)2D3 to dose-
dependently suppress brown adipocyte differentiation, as evidenced by impaired lipid 
accumulation and brown marker gene expression, including the expression of PPARγ, PGC-1α, 
and UCP1. The mechanisms of such suppression have been explored. As described previously, 
both white and brown adipocyte differentiation rely on PPARγ for proper differentiation [112-
114]. Moreover, PPARγ transcriptional co-activator PGC-1α is crucial in brown adipocyte 
differentiation and mitochondrial gene control in response to cold exposure [115]. As early as 
day 2 (D2) in the differentiation process, 1,25(OH)2D3 dose-dependently suppressed both mRNA 
and protein expression of PPARγ and PGC-1α (Fig. 4D-E). These data indicate that down 
regulation of these key factors elicit suppressive effects on brown adipocyte maturity. 
Consistently, VDR over expression also inhibited basal (D0) mRNA of PPARγ and PGC-1α 
(Fig. 7B). When using PPARγ transactivation reporter assays, it was found that both 
1,25(OH)2D3 and VDR over expression suppressed basal and/or ligand-induced PPARγ 
transactivation (Fig. 8A-B), consistent with the effects of 1,25(OH)2D3 on 3T3-L1 adipocyte 
differentiation [28]. It is believed that an abundance of 1,25(OH)2D3 or VDR competes with 
PPARγ for its dimerization partner retinoid X receptor, thereby suppressing PPARγ 
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transactivation [28]. Presumably, this competition for RXR is the mechanism responsible for the 
1,25(OH)2D3/VDR signal suppression of brown adipocyte differentiation. 
 When comparing the suppressive effects of 1,25(OH)2D3 on brown adipocyte marker 
gene expression and mitochondrial contents (Fig. 4D-F) during the 6 day span of  differentiation, 
there is a notable trend of maximum suppression at D4 and recovery on D6. PGC-1α expression 
was maximally suppressed at D4 but the suppression was diminished by D6 (Fig. 4D-E). This 
expression pattern was consistent with the changes of mitochondrial content by 1,25(OH)2D3 
(Fig. 4F). As mature adipocytes at D6, only protein expression of PPARγ, but not PGC-1α, was 
suppressed. Suppressed PPARγ may explain the suppression of UCP1 since PPARγ is required 
for normal BAT differentiation which includes the expression of its hallmark protein, UCP1. 
Cellular bioenergetics results revealed that maximal OCR and OCR from proton leak (i.e., 
uncoupled respiration) (Fig. 6D, F), but not ATP-generating OCR and spare respiration capacity 
(Fig. 6E, G), were affected by 1,25(OH)2D3. These data are consistent with 1,25(OH)2D3-
diminished UCP1 expression, not of mitochondrial content, at D6. The gene expression results of 
1,25(OH)2D3 on UCP1 expression agree with previous  findings of increased UCP1 mRNA in the 
BAT of VDR knockout mice and decreased UCP1 mRNA in the BAT of transgenic mice of 
adipose-specific VDR over-expression. Despite the published results and the current findings, 
the impact of 1,25(OH)2D3/VDR on mitochondrial content and PGC-1α expression in the BAT 
of these mice models is unclear. Whether 1,25(OH)2D3/VDR modulates UCP1 expression and 
brown adipose tissue development through direct effects or through modulation of mitochondrial 
biogenesis (via PGC-1α) in brown adipose tissue in vivo remain to be determined. In addition, 
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differential effects of 1,25(OH)2D3 on PPARγ as opposed to PGC-1α also need to be measured 
in the future. 
 Apart from classical brown adipocytes present in BAT, “browning” of WAT indicated by 
adoption of a brown phenotype (i.e. UCP1 expression) in response to specific stimuli such as 
chronic cold exposure and β-adrenergic stimulation, has been reported in animal models. Due to 
the potential for energy modulation, mechanisms underlying the browning process have been a 
the target of investigation [116]. Thus, discovering that UCP1 mRNA and protein were 
significantly elevated in WAT of VDR knockout mice [117] suggests that VDR may be a 
negative regulator for WAT browning. It would be beneficial to examine the impact of the 
1,25(OH)2D3/VDR system in cultured BAT progenitor cells and in animal models.  
 The existing data describing the suppressive effects of the vitamin D/VDR complex in 
3T3-L1 cell differentiation [27, 28] in combination with the current findings revealing similar 
suppression in brown adipocytes seems to contradict the results of in vivo studies. In my studies, 
the vitamin D/VDR complex impaired both development and UCP1 expression. When compared 
to wild type mice, VDR knockout mice presented with decreased white and brown adipose 
masses but presented with increased UCP1 in the BAT [30, 117]. Alternatively, VDR over-
expression in transgenic mice [31] had increased brown and white adipose tissue masses but 
recorded decreased UCP1. Whether or not the exchange of enlarged BAT mass for enhanced 
UCP1 expression, and vice versa, yields the same power of thermogenesis and energy 
expenditure is unknown. Moreover, the reasons and molecular basis for the inconsistency 
between in vitro and in vivo results are unclear. It appears that both the global inactivation of 
VDR and global over expression of VDR starting from embryonic stages of BAT development 
does not in produce the exact opposite of 1,25(OH)2D3/VDR on brown adipocyte differentiation 
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in cultured cells. The generation and characterization of mice with brown adipose-specific and/or 
temporally inducible VDR knockout mice will be informative in understanding the role of 
1,25(OH)2D3/VDR on BAT development and function in vivo. 
 Our research provides advanced understanding of the suppressive effects of the 
1,25(OH)2D3 /VDR complex on the differentiation brown adipocytes and the functionality of 
mice-derived brown adipocyte cell line. Moreover, our results suggest critical role of both the 
vitamin D3 ligand and VDR in modulation of BAT development and function in models of 
obesity. 
 
4.3 Future Directions 
Both clinical and epidemiological human studies correlate serum 25(OH)D3 with obesity 
as determined by BMI, fat mass, and waist circumference [110]. Low serum 1,25(OH)2D3 levels 
are associated with higher BMI in healthy and obese individuals [118]. However, because of the 
fat solubility of vitamin D2 and vitamin D3, it is unclear whether the low serum levels of 
25(OH)D3  and 1,25(OH)2D3 reflect the total levels of vitamin D3, or are unfair representations 
due sequestration of various forms of vitamin D3 in the fat tissue. For this reason, further 
investigation must be initiated to understand the true availability of vitamin D and its analogs. 
With true understanding of vitamin D availability in adipose tissue, one can better understand the 
relationship between vitamin D status and the development and function of WAT and BAT.   
Moreover, a review of the literature strongly suggests that moderate doses (i.e., 10-8 mM 
or 10 nM) of 1,25(OH)2D3 suppresses 3T3-L1 adipocyte differentiation [27, 28]. However, it has 
been reported that a similar doses of 1,25(OH)2D3 actually promote the differentiation of human 
subcutaneous preadipocytes [29]. Clearly, more research is required to definitively describe the 
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role of 1,25(OH)2D3/VDR in human brown adipocyte differentiation and in the modulation of 
both WAT and BAT in the development of obesity in humans. 
In light of my results, the next logical step would be to test my hypothesis and confirm 
my findings in an in vivo mouse model. It will be informative to determine if a diet enriched with 
vitamin D would modulate the mass and function of BAT as well as WAT. The experimental 
mice will be fed with the current daily allowance recommendation of 600 IU or 15mcg [119, 
120], modified to be appropriate for the body mass of a mouse. The total mass of BAT and WAT 
will be determined together with whole body energy expenditure and other markers indicative of 
metabolic health (e.g. fasting glucose level, lipid panels, glucose tolerance and insulin sensitivity 
among others). It would be useful if these studies were conducted in models of both diet-induced 
obesity and genetic obesity to examine the in vivo role of the vitamin D system in BAT of obese 
animals.  
Another route of exploration would be to knockdown VDR in vivo. Ideally, an agent that 
with BAT specificity would be created to antagonize the vitamin D3 ligand or to knockdown the 
expression of VDR in this tissue so to promote the beneficial effects on BAT but avoid the side 
effects of vitamin D3 deficiency in other various tissues. Thus, promoting the beneficial effects in 
BAT while preserving the activity and function in the remaining tissues and organs of the body.  
Upon knockdown, measurements of the subsequent changes in BAT function and metabolic 
health of the mouse would be recorded.  
With success of this study, the hypothesis would then require a human study. 
Measurements of adipose tissue (as opposed to serum) vitamin D status, body weight, energy 
expenditure, brown adipose mass and activation, and browning of WAT after VDR knockdown 
would be required to draw any conclusions regarding the capacity for vitamin D to manipulate 
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BAT development and function. If the results yield a positive effect in human metabolic health, 
targeted therapy options could then be developed.  
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Fig. 1 Endogenous metabolism of Vitamin D3 
When exposed to ultraviolet light, precursor 7-dehydrocholesterol in the skin is structurally changed. The change 
allows for transportation in the blood to the liver for hydroxylation at the 25th carbon, yielding 25(OH)D3, the major 
circulating form of vitamin D. 25(OH)D3 is then hydroxylated at the 1st or 24th carbon, resulting in either 
1,25(OH2)D3 or 24,25(OH)2D3 respectively, determining the fate of the vitamin.  
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Fig. 2 mRNA expression of VDR and CYP27B1 in mice models of obesity  mRNA expression of VDR and 
CYP27B1 of the BAT from the male ob/ob or wild type control mice (n=6) (A) and from the male DIO or 
chow-fed control mice (n=7) (B) were analyzed. Relative mRNA expression was normalized to 36B4 and 
expressed as fold of the controls (set as 1). Data are mean±SE (n=6 or 7). *, significantly different from the 
controls with p<0.05.!
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Fig. 3 mRNA expression of VDR, CYP24A1 and CYP27B1 during brown adipocyte differentiation  Brown preadipocytes were 
differentiated into adipocytes in culture within 6 days. mRNA expression of VDR (A), CYP24A1 (B), and CYP27B1 (C) at day 0 
(D0), 2 (D2), 4 (D4) and 6 (D6) were analyzed. Relative mRNA expression was normalized to 36B4 and expressed as fold of D0 
value (set as 1). Data are mean±SE (n=3). Different letters indicate significant difference (p < 0.05). 
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Brown preadipocytes were differentiated into adipocytes in culture within 6 d ys. mRNA expression of 
VDR (A), CYP24A1 (B), and CYP27B1 (C) at day 0 (D0), 2 (D2), 4 (D4) and 6 (D6) were analyzed. 
Relative mRNA expression was normalized to 36B4 and expressed as fold of D0 value (set as 1). Data are 
mean±SE (n=3). Different letters indicate significant difference (p < 0.05). 
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Fig. 4 1,25(OH)2D3 dose-dependently suppresses brown adipocyte differentiation   
Brown preadipocytes were differentiated in the presence of increasing doses of 1,25(OH)2D3 (1, 10, 100 nM) 
or the vehicle control DMSO as shown in the top panel of (A). Oil red O (ORO) stained lipid accumulation is 
shown in the low panel of (A). ORO stained cell morphology is shown in (B). ORO absorbance was measured 
and plotted in (C). Different letters indicate significant difference (p < 0.05) in (C). mRNA expression of 
brown adipocyte markers PPARγ, PGC-1α, PPARγ, UCP-1, Nrf-1, Cidea, Cox4a, and Vit D3 target gene 
CYP24A1 were analyzed (D). Relative mRNA expression was normalized to 36B4 and expressed as fold of 
D0 value (set as 1). (E) Protein expression of PPARγ, PGC-1, and UCP-1 was analyzed by western blot. (F) 
Mitochondrial content was analyzed by mitochondrial specific fluorescence dye mitoTracker green at D4 and 
D6. Relative fluorescence intensity was calculated from the mean fluorescence intensity values of the samples 
and expressed as fold of the controls. 
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Fig. 4 1,25(OH)2D3 dose-dependently suppresses brown adipocyte differentiation   
Brown preadipocytes were differentiated in the presence of increasing doses of 1,25(OH)2D3 (1, 10, 100 nM) or the vehicle 
control DMSO as shown in the top panel of (A). Oil red O (ORO) stained lipid accumulation is shown in the low panel of 
(A). ORO stained cell morphology is shown in (B). ORO absorbance was measured and plotted in (C). Different letters 
indicate significant difference (p < 0.05) in (C). mRNA expression of brown adipocyte markers PPARγ, PGC-1α, PPARγ, 
UCP-1, Nrf-1, Cidea, Cox4a, and Vit D3 target gene CYP24A1 were analyzed (D). Relative mRNA expression was 
normalized to 36B4 and expressed as fold of D0 value (set as 1). (E) Protein expression of PPARγ, PGC-1, and UCP-1 was 
analyzed by western blot. (F) Mitochondrial content was analyzed by mitochondrial specific fluorescence dye mitoTracker 
green at D4 and D6. Relative fluorescence intensity was calculated from the mean fluorescence intensity values of the 
samples and expressed as fold of the controls. 
 
 
 
Fig. 4 Continued   
 
  56 
 
  
Fig. 5 Effects of 1,25(OH)2D3 treatment timing on brown adipocyte differentiation  (A, B) 
Brown preadipocytes were differentiated in the presence of 1,25(OH)2D3 (100 nM) or the vehicle 
control DMSO according to the diagrams. At the end of differentiation, ORO absorbance was 
measured and plotted. Data are mean±SE (n=3). Different letters indicate significant difference (p 
< 0.05) among 1,25(OH)2D3-treated white bars. *, **, significantly different from the controls 
with p<0.05 and p<0.01, respectively. 
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Fig. 6 Effects of 1,25(OH)2D3 on mitochondrial respiration in brown adipocytes   
Brown preadipocytes were differentiated in the presence or absence of increasing doses of 
1,25(OH)2D3 until day 6. The cells were then sub-cultured in 24-well XF assay plates overnight and 
were subjected to real-time measurements of oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR). Following isoproterenol (ISO, 1µM) injection, the mitochondrial 
complex inhibitors were injected sequentially in the following order: oligomycin (1 µM), FCCP 
(0.75 µM), antimycin A/rotenone (1 µM each), and the readings were taken after each inhibitor. The 
OCR (A) and ECAR (B) readings were plotted over time. ISO-stimulated OCR was shown in (C). 
Calculated maximal OCR (D), ATP-generating OCR (E), OCR from proton leak (F), Spare 
respiration capacity (G) were shown.  Data are mean±SE (n=6-9). *, **, significantly different from 
the controls with p<0.05 and p<0.01, respectively. 
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Fig. 7 Over-expression of VDR suppresses brown adipocyte differentiation   
Brown preadipocytes were stably transfected with murine VDR expression plasmid, or a vector 
plasmid. Pools of stably transfected cells were subjected to brown adipocyte differentiation. (A) Basal 
mRNA expression of VDR, CYP24A1, and CYP 27B1 were shown in the left panel. The relative 
mRNA expression was normalized to 36B4 and expressed as fold of the vector value (set as 1). 
Protein expression of the Flag-tagged exogenous VDR was shown in the right panel. (B) mRNA 
expression of brown adipocyte marker UCP-1, PGC-1α, and PPARγ at basal (D0) and D4 in the 
differentiation were shown. The relative mRNA expression was normalized to 36B4 and expressed as 
fold of D0 value (set as 1). Data are mean±SE (n=3). *, **, significantly different from the controls 
with p<0.05 and p<0.01, respectively. 
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Fig. 8 1,25(OH)2D3/VDR suppress PPARγ  transactivation in brown preadipocytes  (A) 
Brown preadipocytes were transiently transfected with PPARγ transactivation reporters and β-
galactosidase expression plasmid for 24 hr, the cells were then pre-treated with increasing doses 
of 1,25(OH)2D3 (1, 10, and 100 nM) overnight, followed by co-treatment with rosiglitazone (Rosi, 
1 µM) for 8 hr. (B) Brown preadipocytes were transiently transfected with PPARγ transactivation 
reporters, β-galactosidase, and murine VDR expression plasmid or a vector control plasmid for 24 
hr. The cells were then treated with rosiglitazone (Rosi, 1 µM) for 8 hr. Cell lysate was prepared 
and luciferase and β-galactosidase activities were measured. PPARγ transactivation is presented 
as fold of relative luciferase activities to that of the controls (set as 1). Data are mean±SE (n=3). 
The bars indicate dose-dependent response in (A). *, p<0.05. 
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